Home
A Different Class of ADT
Control CV Risk
Economic Burden of CVD Events
Disease-Related Symptoms
Delay Disease Progression
Patient Satisfaction
Support & Resources
Dosing & Administration
Firmagon Licence
Prescribing Information
FIRMAGON® can delay disease progression1,2,5
Time is incredibly valuable to you and your patients. See how FIRMAGON® can give you more.
Learn More...
FIRMAGON® increases PSA progression-free survival at 12 months vs. LHRH agonists1,5
FIRMAGON® delays PSA failure or death by 7 months (secondary endpoint)2*,**,†
- Delays PSA failure or death by 7 months in high-risk patients** and can maintain this response long-term2
- Increases PSA progression-free survival at 12 months,1 with response maintained to 5 years in significantly more high-risk patients vs. LHRH agonists2
Adapted from Boccon-Gibod L, et al. 2012
*In a long-term extension of a Phase 3 trial. Delay defined as time taken for 25% of patients considered to be at high-risk (with a baseline PSA ≥ 20 ng/ml) to experience PSA failure or death (TTP 25%).
TTP25% was significantly longer with FIRMAGON® than leuprorelin (514 vs. 303 days, p=0.001).
**As calculated using the Weibull estimate.
† The primary endpoint of the trial was suppression of testosterone to ≤ 0.5 ng/ml at all monthly measurements from day 28 to day 364
FIRMAGON® provides effective treatment for high-risk prostate cancer patients1-3
*High risk defined as patients with baseline PSA ≥20 ng/ml.1,2
